iiinova — where your digital self keeps evolving

Aakash Desai @adesaimd.bsky.social · 07/01/2025

Completely agree with this! So many biopsies are done without a clear plan on how the biological samples would help move things forward!

010

Aakash Desai @adesaimd.bsky.social · 21/12/2024

🔍 Does AI reduce #clinician workload? @NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️ 💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos #AIinMedicine #LLMs @oncoalert.bsky.social

375

Aakash Desai @adesaimd.bsky.social · 18/12/2024

🚨 Breakthrough therapy for ES-SCLC! @FDA grants sacituzumab govitecan BTD for ES-SCLC progressing on platinum chemo, based on phase II TROPiCS-03 data: 🔹 ORR: 41.9% 🔹 Disease control: 83.7% 🔹 Clinical benefit: 48.8% Next step: phase III trials. 🤞 this provides another option #LCSM #SCLC

092

Aakash Desai @adesaimd.bsky.social · 11/12/2024

Absolutely stunning progress in #lcsm! 🫁 📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉 ✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social

0114

Aakash Desai @adesaimd.bsky.social · 09/12/2024

Completely agree! From my experience with testing companies, there’s often clarity on next steps but hesitancy in designing trials that truly assess the ‘value’ of tests. We can’t keep adding data to similar studies without meaningful progress.

050

Aakash Desai @adesaimd.bsky.social · 05/12/2024

Phase I Results AMG 193, PRMT5 inhibitor targeting MTAP-deleted solid tumors: @AnnalsOncology • 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary) • 🛡️ Safety: minimal myelosuppression; nausea & fatigue • 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social

074

Aakash Desai @adesaimd.bsky.social · 05/12/2024

📢 Breaking news in #SCLC treatment! Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73). This approval marks an important step forward for patients with limited-stage SCLC! 💪

173

Aakash Desai @adesaimd.bsky.social · 04/12/2024

Just an amazing episode! Kudos @drcamidge.bsky.social, so touching! Dr. Camidge puts it so beautifully “Patients are people who happen to be patients and not patients who happen to be people, if you see what I mean.” Must listen 🎧

podcasts.apple.com

Camidge and Turner Reflect on the Importance of Care and Connection Throughout the Cancer Journey

Podcast Episode · How This Is Building Me · 05/04/2023 · 46m

010

Reposted by Aakash Desai

Patrick Forde @patrickforde.bsky.social · 02/12/2024

Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca. www.businesswire.com/news/home/20...

businesswire.com

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoi

061

Reposted by Aakash Desai

Giannis Mountzios MD @drgreeklungcancer.bsky.social · 01/12/2024

A strategic position statement in @Annals_Oncology on the main actions to boost #lungcancer research and innovation: ✅ Pragmatic trials ✅ Ensure inclusivity and diversity ✅ NGS in resectable #NSCLC ✅ Exploit resistance mech ✅Focus on novel Tox bit.ly/4ga8LlC #LCSM #some @iaslc.bsky.social

073

Reposted by Aakash Desai

Toni Choueiri, MD @drchoueiri.bsky.social · 30/11/2024

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR! www.nature.com/articles/s41...

13711

Reposted by Aakash Desai

Jennifer A. Marks, MD @jennifermarksmd.bsky.social · 01/12/2024

aacrjournals.org/cancerres/ar... Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer #lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social

063

Aakash Desai @adesaimd.bsky.social · 27/11/2024

Thrilled to be starting “AI in Health Care: From Strategies to Implementation program” @harvardmed! 🧠💻 Embarking on this to deepen my understanding and applications of AI to revolutionize #medicine and #oncology! Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife

010

Reposted by Aakash Desai

Jyoti Malhotra, MD, MPH @jyotimalhotra.bsky.social · 27/11/2024

Thanks to our amazing patient who brought in delicious White Ribbon cupcakes for the thoracic clinic team to celebrate #LungCancerAwarenessMonth #COH

0111

Aakash Desai @adesaimd.bsky.social · 26/11/2024

🧬 “Real-world Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC” The IFCT-2004 BLaDE study confirms: • Significant efficacy in both pretreated & untreated patients • 12-month OS: 67.4% • Median PFS: 10.4 (2L+), 18.2 mths (1L) 🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯

042

Reposted by Aakash Desai

Nathan Pennell MD, PhD, FASCO @n8pennell.bsky.social · 25/11/2024

Honored to be nominated for ASCO Board of Directors along with 12 other qualified candidates. Only one week remaining to vote and make your voice heard! society.asco.org/about-asco/a...

society.asco.org

ASCO Election

1233

Reposted by Aakash Desai

Young Lung Cancer Initiative @younglungcancer.bsky.social · 23/11/2024

Anyone can get lung cancer. Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys. Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social #BecauseofResearch #LCSM

0123

Aakash Desai @adesaimd.bsky.social · 23/11/2024

Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer - @ClinicalLung ◾️ Median OOP cost of $98 (IQR: $43.8-$306.5) ◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa

030

Aakash Desai @adesaimd.bsky.social · 23/11/2024

So #oncosky peeps, how are you using your #SoMe time these days? 1. BlueSky Only 2. X and BlueSky 3. X, BlueSky and LinkedIn 4. X, BlueSky, LinkedIn and Instagram/TikTok/Others? (At this point you have my deep respect 🙏) Also just realized, @bsky.app needs a poll function!!!!

481

Reposted by Aakash Desai

Giannis Mountzios MD @drgreeklungcancer.bsky.social · 22/11/2024

Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social #some #lungcancer

072

Reposted by Aakash Desai

Jack West, MD, FASCO @jackwestmd.bsky.social · 22/11/2024

Flew from Shanghai to Seattle to Lake Tahoe yday to attend #MaTOS24 conference today, where Claudia Henschke kicks off on screening. Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.

1171

Reposted by Aakash Desai

Stephen Liu @stephenvliu.bsky.social · 22/11/2024

Ready to start the #MaTOS24 conference at Lake Tahoe with Drs. Luis Raez and Marina Garassino!

0121

Aakash Desai @adesaimd.bsky.social · 21/11/2024

#FDAOncology approves a biparatopic, Zanidatamab- targeting HER2 for #BTCs Based on HERIZON-BTC-01! ➡️ORR: 41.3%, mDOR=14.9 mths ➡️ Approval for IHC 3+, where TDX-d also has agnostic approval ➡️18% Gr3 TRAEs, diarrhea #Oncosky @oncoalert.bsky.social @viveksubbiah.bsky.social

0123

Aakash Desai @adesaimd.bsky.social · 21/11/2024

Exciting times in #NSCLC with multiple immunotherapy approvals in early stage! 🎉 But navigating these options can be complex. Glad to partner with @OncLearnNetwork to create patient case-based education, bridging the gap between advancements and real-world application. bit.ly/498ffPB

020

Aakash Desai @adesaimd.bsky.social · 21/11/2024

Hello everyone! Jumping on here, and hoping to engage in discussions on all things #oncology, #medicine, #clinicaltrials, #meded and more!!! Excited to ‘soar’ into this community and ‘spread’ knowledge on cancer care. Let’s ‘wing’ it together and make a ‘butterfly’ effect in healthcare!

020